

**What is claimed is:**

1. A replication-competent adenovirus vector comprising a tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) coding region and an ADP coding region.
2. The vector of claim 1, wherein said TRAIL coding region and said ADP coding region are positioned under the control of adenovirus major late promoter (MLP).
3. The vector of claim 1, wherein said TRAIL coding region and said ADP coding region are positioned in the E3 region of said vector.
4. The vector of claim 3, wherein said TRAIL coding region is positioned upstream of said ADP coding region.
5. The vector of claim 3, wherein said TRAIL coding region is positioned downstream of said ADP coding region.
6. The vector of claim 1, wherein said TRAIL coding region is positioned under the control of adenovirus major late promoter (MLP), and said ADP coding region is positioned under the control of another promoter.
7. The vector of claim 1, wherein said ADP coding region is positioned under the control of adenovirus major late promoter (MLP), and said TRAIL coding region is positioned under the control of another promoter.
8. The vector of claim 1, wherein said vector lacks one or more of coding regions for the 6.7K, gp19K, RID $\alpha$ , RID $\beta$  or 14.7K proteins.

9. The vector of claim 8, wherein said vector lacks all of the coding regions for the 6.7K, gp19K, RID $\alpha$ , RID $\beta$  or 14.7K proteins.
10. The vector of claim 1, wherein said vector further comprises at least a first mutation in the E1A region, said mutation impairing binding of E1A to p300 and/or pRB.
11. The vector of claim 10, wherein said vector lacks coding regions for 6.7K, gp19K, RID $\alpha$ , RID $\beta$  or 14.7K proteins, and said TRAIL coding region is positioned upstream of said ADP coding region.
12. The vector of claim 1, wherein said vector lacks coding regions for 6.7K, gp19K, RID $\alpha$ , RID $\beta$  or 14.7K proteins, contains a wild-type E1A coding region, and said TRAIL coding region is positioned upstream of said ADP coding region.
13. The vector of claim 10, wherein said vector lacks coding regions for 6.7K, gp19K, RID $\alpha$ , RID $\beta$  or 14.7K proteins, and said TRAIL coding region is positioned downstream of said ADP coding region.
14. The vector of claim 1, wherein said vector lacks coding regions for 6.7K, gp19K, RID $\alpha$ , RID $\beta$  or 14.7K proteins, contains a wild-type E1A coding region, and said TRAIL coding region is positioned downstream of said ADP coding region.
15. The vector of claim 1, wherein said vector is oncolytic.
16. An adenoviral virion comprising a replication-competent adenoviral vector according to claim 1.
17. A host cell comprising the replication-competent adenoviral vector of claim 1

18. A method of inhibiting a hyperproliferative cell comprising contacting said cell with a second cell infected with a replication-competent adenovirus vector comprising a tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) coding region and an ADP coding region.
19. The method of claim 18, wherein inhibiting comprises inhibiting cell division, inhibiting cell growth, inducing cell cycle arrest, inducing apoptosis or lysing.
20. The method of claim 18, wherein said hyperproliferative cell is a cancer cell.
21. The method of claim 18, wherein said second cell is a cancer cell.
22. The method of claim 20, wherein said cancer cell is a lung cancer cell, a prostate cancer cell, a colon cancer cell, an ovarian cancer cell, a testicular cancer cell, a brain cancer cell, a stomach cancer cell, a uterine cancer cell, a breast cancer cell, an esophageal cancer cell, a head & neck cancer cell, a pancreatic cancer cell, a liver cancer cell, a kidney cancer cell, a skin cancer cell or a blood cancer cell.
23. A method of treating a subject with a hyperproliferative cell disorder comprising administering to said subject a replication-competent adenovirus vector comprising a tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) coding region and an ADP coding region.
24. The method of claim 23, wherein said hyperproliferative all disorder is cancer.
25. The method of claim 24, wherein said cancer is lung cancer, prostate cancer, colon cancer, ovarian cancer, testicular cancer, brain cancer, stomach cancer, uterine cancer, breast cancer, esophageal cancer, head & neck cancer, pancreatic cancer, liver cancer, kidney cancer, skin cancer or blood cancer.

26. The method of claim 23, wherein said subject is a human.
27. The method of claim 23, further comprising administering to said subject a second therapy.
28. The method of claim 23, wherein said second therapy is chemotherapy, radiotherapy, immunotherapy, hormonal therapy, gene therapy or surgery.
29. The method of claim 23, wherein said second therapy is provided prior to said replication-competent adenovirus vector.
30. The method of claim 23, wherein said second therapy is provided after said replication-competent adenovirus vector.
31. The method of claim 23, wherein said second therapy is provided at the same time as said replication-competent adenovirus vector.
32. The method of claim 23, wherein said replication-competent adenovirus vector is administered more than once.
33. The method of claim 23, wherein said replication-competent adenovirus vector is administered intratumorally, locally to said tumor, regionally to said tumor or systemically.
34. The method of claim 23, wherein said replication-competent adenovirus vector is administered intravenously, intraarterially, intramuscularly, intralymphatically, intraperitoneally or subcutaneously.
35. The method of claim 23, wherein said TRAIL coding region and said ADP coding region are positioned under the control of adenovirus major late promoter (MLP).

36. The method of claim 23, wherein said TRAIL coding region and said ADP coding region are inserted into the E3 region.
37. The method of claim 36, wherein said TRAIL coding region is positioned upstream of said ADP coding region.
38. The method of claim 36, wherein said TRAIL coding region is positioned downstream of said ADP coding region.
39. The vector of claim 23, wherein said TRAIL coding region is positioned under the control of adenovirus major late promoter (MLP), and said ADP coding region is positioned under the control of another promoter.
40. The vector of claim 23, wherein said ADP coding region is positioned under the control of adenovirus major late promoter (MLP), and said TRAIL coding region is positioned under the control of another promoter.
41. The method of claim 23, wherein said vector lacks one or more of coding regions for the 6.7K, gp19K, RID $\alpha$ , RID $\beta$  or 14.7K proteins.
42. The method of claim 41, wherein said vector lacks all of the coding regions for the 6.7K, gp19K, RID $\alpha$ , RID $\beta$  or 14.7K proteins.
43. The method of claim 23, wherein said vector further comprises at least a first mutation in the E1A region, said mutation impairing binding of E1A to p300 and/or pRB.
44. The method of claim 24, wherein said cancer is a multi-drug resistant cancer.

45. The method of claim 23, wherein treating comprises reducing tumor size, reducing tumor growth, inducing remission, inducing tumor necrosis, or prolonging patient survival.
46. A method of rendering an inoperable tumor operable comprising administering to a subject a replication-competent adenovirus vector comprising a tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) coding region and an ADP coding region.
47. A method of treating metastatic cancer in a subject comprising administering to subject a replication-competent adenovirus vector comprising a tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) coding region and an ADP coding region.
48. A method of preventing cancer in a subject at risk thereof comprising administering to said subject a replication-competent adenovirus vector comprising a tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) coding region and an ADP coding region.
49. A method of treating recurrent cancer in a subject comprising administering to said subject a replication-competent adenovirus vector comprising a tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) coding region and an ADP coding region.